INS and metabolic dysfunction-associated steatotic liver disease: Based on previous studies showing the effects of niclosamide and its salt forms NEN and NPP on hepatic steatosis, we sought to establish a cell-based disease model of NAFLD using insulin and the LXR agonist T0901317 to stimulate de novo hepatic lipid accumulation to study the effects of related N-substituted Phenylbenzamides on steatosis in a non-neoplastic human hepatocyte cell line, PH5CH8 [27].